Forty million people around the world now live with HIV/AIDS, the majority in sub-Saharan Africa. In the East African countries of Kenya, Tanzania and Uganda alone, nearly seven million men, women and children are infected with HIV. Despite the fact that the developing world is the epicenter of the HIV/AIDS pandemic, most research initiatives and treatment guidelines have been developed using patient populations from resource-rich areas. While important clinical protocols and treatment guidelines have emerged from these research initiatives they may not successfully transfer to the vast majority of HIV/AIDS patients who live in resource-poor areas. As an example, while most clinical protocols have been developed among populations infected with HIV-1 subtype B, the predominant strain in the developed world, in sub-Saharan Africa, in general, and East Africa, in particular, a variety of HIV-1 non-B subtypes are found. This fact may have far-reaching implications for critical aspects of antiretroviral treatment, including the timing of initiation of antiretroviral therapy and development of resistance to first-line regimens. Also, due to poverty, malnutrition and the existence of various infectious diseases not commonly encountered in more resource-rich parts of the world, such as malaria, tuberculosis, and waterborne pathogens, treatment and care of HIV-infected patients in sub-Saharan Africa is uniquely complex as compared to more prosperous regions of the globe. Indiana University, with partners at the University of California San Francisco, Columbia University, Yale University, Moi University in Kenya and Mbarara University in Uganda and support from the World Health Organization and various agencies and private foundations, have established a number of extensive HIV/AIDS treatment and research networks in the East African nations of Kenya, Uganda, and Tanzania. With this application we aim to create a regional Data Center for East Africa as part of the IEDEA Consortium. This Center will not only merge and share data among current and future partners, but also offer unparalleled research capacity to identify and address questions that are amendable to combined regional database analysis. Our East Africa Regional IEDEA Consortium will fulfill the following functions: 1) Identify data from existing HIV/AIDS care and research networks in the East Africa region;2) Develop protocols to harmonize and merge data and provide training and education to accomplish this task;3) Share data within the East Africa Regional Consortium, the worldwide IEDEA Consortium, and collaborating investigators from the broader scientific community;4) Identify and pursue critical questions related to HIV/AIDS care, treatment and research that can be addressed with combined regional data. Particular emphasis will be placed on HIV-related questions that have broad applicability across regions and populations.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01AI069911-05S1
Application #
8129128
Study Section
Special Emphasis Panel (ZAI1-JB-A (J3))
Program Officer
Zimand, Lori B
Project Start
2010-08-26
Project End
2011-07-31
Budget Start
2010-08-26
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$498,226
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
603007902
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Siika, Abraham; McCabe, Leanne; Bwakura-Dangarembizi, Mutsa et al. (2018) Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clin Infect Dis 66:S140-S146
Vreeman, Rachel C; Ayaya, Samuel O; Musick, Beverly S et al. (2018) Adherence to antiretroviral therapy in a clinical cohort of HIV-infected children in East Africa. PLoS One 13:e0191848
Olney, Jack J; Eaton, Jeffrey W; Braitstein, Paula et al. (2018) Optimal timing of HIV home-based counselling and testing rounds in Western Kenya. J Int AIDS Soc 21:e25142
Holmes, Charles B; Yiannoutsos, Constantin T; Elul, Batya et al. (2018) Increased prevalence of pregnancy and comparative risk of program attrition among individuals starting HIV treatment in East Africa. PLoS One 13:e0190828
Mukerji, Shibani S; Misra, Vikas; Lorenz, David R et al. (2018) Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States. Clin Infect Dis 67:1182-1190
Hakim, James G; Thompson, Jennifer; Kityo, Cissy et al. (2018) Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Lancet Infect Dis 18:47-57
IeDEA and COHERE Cohort Collaborations (2018) Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clin Infect Dis 66:893-903
Hu, Liangyuan; Hogan, Joseph W; Mwangi, Ann W et al. (2018) Modeling the causal effect of treatment initiation time on survival: Application to HIV/TB co-infection. Biometrics 74:703-713
Haas, Andreas D; Zaniewski, Elizabeth; Anderegg, Nanina et al. (2018) Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc 21:
Wools-Kaloustian, Kara; Marete, Irene; Ayaya, Samuel et al. (2018) Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. J Acquir Immune Defic Syndr 78:221-230

Showing the most recent 10 out of 121 publications